John Ford, Enterprise Therapeutics CEO
January 29, 2024 04:00 AM EST
Financing

Ex­clu­sive: UK biotech rais­es $33.1M to test CF drug that could work on top of stan­dard of care

Katherine Lewin

News Reporter

En­ter­prise Ther­a­peu­tics closed a £26 mil­lion Se­ries B round to fund a Phase IIa tri­al of its cys­tic fi­bro­sis drug, which aims to sig­nif­i­cant­ly im­prove …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times